0001838780-21-000001.txt : 20210104 0001838780-21-000001.hdr.sgml : 20210104 20210104140044 ACCESSION NUMBER: 0001838780-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c ITEM INFORMATION: 4a5 FILED AS OF DATE: 20210104 DATE AS OF CHANGE: 20210104 EFFECTIVENESS DATE: 20210104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hemispherian AS CENTRAL INDEX KEY: 0001838780 IRS NUMBER: 000000000 STATE OF INCORPORATION: Q8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-385080 FILM NUMBER: 21501169 BUSINESS ADDRESS: STREET 1: GAUSTADALLEEN 21 CITY: OSLO STATE: Q8 ZIP: 0349 BUSINESS PHONE: 4746390867 MAIL ADDRESS: STREET 1: GAUSTADALLEEN 21 CITY: OSLO STATE: Q8 ZIP: 0349 D 1 primary_doc.xml X0708 D LIVE 0001838780 Hemispherian AS GAUSTADALLEEN 21 OSLO Q8 NORWAY 0349 4746390867 NORWAY None None Corporation true 2020 Adam Brian Robertson Avstikkeren 9 Oslo Q8 NORWAY 1156 Director Zeno Albisser Teglverksgata 7A Oslo Q8 NORWAY 0553 Executive Officer Director Anett Monika Diaz Lagdalen 55 Vettre Q8 NORWAY 1392 Director Terezia Prikrylova Thor Olsens gate 8A Oslo Q8 NORWAY 0177 Director Pharmaceuticals $1 - $1,000,000 06c 4a5 false 2020-12-18 false true false 20000 57713 57713 0 Internationally, the total offering was USD 407,418. However, only shares with a total value of USD 57,713 were offered to two specific individual investors in the US. false 2 0 0 No commissions or finders' fees are paid. 10000 true The proceeds will be matched with Norwegian grant funding and will be used to fund pre-clinical pharmaceutical development, including salaries for employees. false Hemispherian AS Adam Robertson Adam Brian Robertson CSO 2021-01-04